Back to search

Peptide record

TPDB32196

LALF32–51 Cell-penetrating Peptides Hemolysis Toxicity standard
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB32196
LALF32–51
Cell-penetrating Peptides Hemolysis Toxicity
Toxicity and safety peptides Delivery and barrier-penetrating peptides
CPPsite3.0 HemoPI Hemolytic2 Peptipedia
standard
No
A 20-aa standard natural multi-activity (Cell-penetrating Peptides, Hemolysis, and Toxicity) peptide sequence curated from CPPsite3.0, HemoPI, Hemolytic2, and other sources, with an available 3D structural model.
Sequence
HYRIKPTFRRLKWKYKGKFW
Physicochemical Analysis
C135H200N38O24
ANDCEQMSV
K
2739.31
11.62
9
0
8
+8
0.23
-1.470
39.00
Mammalian: 3.5 hour Yeast: 10 min E.coli: >10 hour
13980
510.35
3
Residue Composition
number
0
A
3
R
0
N
0
D
0
C
0
E
0
Q
1
G
1
H
1
I
1
L
5
K
0
M
2
F
1
P
0
S
1
T
2
W
2
Y
0
V
Amino Acid Distribution
A: 0 R: 3 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 1 L: 1 K: 5 M: 0 F: 2 P: 1 S: 0 T: 1 W: 2 Y: 2 V: 0
Chemical Descriptors
20
C135H200N38O24
2739.31
11.62
+8
0.23
-1.470
Free
L
Linear
Free
N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)O
Evidence Records 2 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

H460, Ht-29, H460-Nf-Κb-Hrgfp 2G6, And Ht-29-Nf-Κb-Hrgfp E5 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L
Protein derived
CIGB-552 maintains the cell-penetrating capacity and shows a higher antitumor effect compared to LALF32–51 and L-2
In vitro
CTTSCTTTTSCCCCSSSCC
Evidence 2 Hemolysis

Source & Reference

HemoPI
NA
Additional Detail Fields 1 fields
CTTSCTTTTSCCCCSSSCC